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 Abstract  
Little is known about how combining efficacious HIV prevention interventions could lead to HIV 
elimination. We used an agent-based simulation model, the HIV Calibrated Dynamic Model (HIV-CDM), 
to assess the potential for HIV elimination in South Africa. We examined several scenarios (from 
continuation of current status quo to perfect targets) with differing combinations of male condoms, adult 
male circumcision, HIV testing, and early antiretroviral therapy (ART). We varied parameters including: 
proportion of adult males circumcised, frequency of condom use in sex acts, HIV test acceptance, linkage 
to care, ART initiation criteria, ART suppression rates, and loss to follow up. Maintaining current levels 
of combination prevention will lead to increasing HIV incidence and prevalence while the perfect 
combination scenario is projected to eliminate HIV on a 50-year time scale from 2013 to 2063. Perfecting 
testing and treatment, without changing condom use or circumcision rates, resulted in 89% incidence 
reduction but not elimination. Universal adult male circumcision alone resulted in a 21% incidence 
reduction within 20 years. Substantial decreases in HIV incidence are possible from sufficient uptake of 
both primary prevention and ART, but with continuation of the status quo, HIV elimination in South 
Africa is unlikely within a 50-year time scale.  
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Researchers and public health officials are cautiously optimistic that the interventions needed to control 
and potentially eliminate HIV have been identified, but these interventions are inadequately and 
ineffectively used in many populations. The number of available interventions to curb horizontal HIV 
transmission has increased as successful trials have proven the efficacy of oral pre-exposure prophylaxis 
(1-4), treatment as prevention (5), and vaginal microbicides (6). Primary prevention methods, such as 
condoms (7) and adult male circumcision (8-11), can reduce transmission risk in the absence of 
antiretroviral treatment. Trials attempting to demonstrate the possibility of control and elimination of HIV 
in large populations are currently being conducted in Sub-Saharan Africa by scaling up combinations of 
independently successful HIV intervention programs (12-15).  
 
Along with these trials, mathematical models have been developed to simulate strategies to achieve 
elimination, defined here as a reduction of HIV incidence to less than one infection per 100,000 person-
years (16, 17). Two main types of mathematical models have been used to model HIV transmission: 
compartmental models track the progress of groups of individuals grouped by particular characteristics 
(often infection/disease stage) (18) and agent-based models simulate individuals and include individual-
level behavior and/or disease progression (19, 20). Agent-based models are especially useful when there 
is a great deal of heterogeneity and complexity in behavior and biology as observed in HIV epidemics 
(see (21) for more detail) (22-24).  
 
Several mathematical models have been developed to address the potential for HIV elimination using 
treatment as prevention and have come to a variety of conclusions about its timeline and feasibility (25-
33). While differences in model parameterization and structure have little influence on short term 
projections (32, 33), some modelers have reported that longer-term elimination is possible even with 
imperfect testing and treatment interventions (25, 32). Few have studied the change in incidence and the 
potential for elimination when combinations of non-treatment focused programs, such as condom and 
circumcision campaigns, are implemented with existing treatment expansion strategies.  In light of 
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UNAIDS’s recent fast-track guidelines, which were motivated by mathematical models, it is important to 
examine progress towards elimination through multiple methods (34). Using the HIV Calibrated Dynamic 
Model (HIV-CDM) (35), we perform agent-based simulations to estimate the treatment as prevention 
conditions, alongside non-treatment focused programs, that could lead to HIV elimination and estimate 
the timeline for this possible elimination.  
 
METHODS 
HIV Calibrated Dynamic Model (HIV-CDM) Overview 
The HIV-CDM is an agent-based HIV transmission model that has been calibrated to South African 
prevalence and sexual behavior data from 1990-2002 using a Bayesian melding-like procedure (35). 
Briefly, the HIV-CDM is linked to the Cost Effectiveness of Preventing AIDS Complications 
International (CEPAC-I) model (36-39) allowing the HIV-CDM to incorporate detailed disease 
progression and sexual behavior parameters when evaluating HIV transmission dynamics. HIV-RNA is 
stochastically assigned by CEPAC-I and, in the absence of treatment, determines the monthly decline in 
CD4 count, which in turn leads to increased risks of opportunistic infections and HIV-related mortality 
(40, 41). Individuals receiving antiretroviral therapy (ART) have reductions in their HIV-RNA, which in 
turn reduces their HIV transmission potential. The HIV-CDM allows individuals to form up to four types 
of heterosexual partnerships (each with a particular partnership duration and number of sex acts per 
month) concurrently, with varying partnership acquisition rates. Individuals of both sexes can be either 
low- or high-risk, forming partnerships at differing rates by the use of a high-risk multiplier. A small 
proportion of females are commercial sex workers (CSW), for whom all partnerships are assumed to be 
one-time transactional.  
 
The sexual mixing algorithm is male-driven; women are chosen for partnerships based on a male’s 
preferred age and risk group. The model tracks HIV transmission on a per-act basis between discordant 
partners. The force of infection is dependent on the infected partners’ HIV-RNA and stage of HIV 
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infection (acute, chronic or late-stage), condom use, and circumcision status of the male partner. Acute 
infection is defined as the first three months after infection; chronic infection follows and continues until 
the individual’s CD4 count drops below 50/mm3 (late-stage infection). Each month, for those infected, 
HIV-RNA, CD4 count, case identification, in-care status, ART status, and opportunistic infections are 
updated from CEPAC-I. Individuals die in the model either due to HIV/AIDS or from non-HIV related 
causes (35).  
 
The HIV-CDM was developed and coded in C++. Each model run is initiated with a total population size 
of 100,000 for a 50-year initialization period and then seeded with 6 HIV cases distributed evenly among 
high-risk individuals of both sexes and CSW. Random number generation was performed with a fixed 
seed in order to reproduce perfect counterfactuals in the absence of treatment and to maintain the validity 
of the calibration procedure. Parameter sets were created for the calibration procedure by simultaneously 
selecting parameter values randomly from pre-specified distributions for 12 parameters (Web Table 1). 
These parameter sets were then tested over three phases of calibration procedures which checked for 
consistent fit to HIV prevalence data, sexual behavior, and incidence data prior to the introduction of 
ART. At the end of the three phases, each of the parameter sets was assigned a normalized likelihood 
weight based on its fit to the national 1990-2003 South African HIV prevalence curve using the 
Levenberg-Marquardt algorithm. This normalized likelihood weight is used to produce a weighted 
average of all outcomes for the parameter sets that passed all three phases of the calibration procedure. 
Additional details of the model structure and calibration have been previously published (35).  
 
Primary Prevention. We define a distribution for the proportion of sex acts in which a condom is used for 
each partnership type at model initiation. Each male randomly draws his own parameters from these 
distributions to determine with what probability he will use condoms for each partnership type. Condom 
usage distributions can be changed at any point in time and males redraw their condom use probability for 
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each partnership type at the start of such an intervention. Condoms are assumed to be 80% effective in all 
scenarios (Web Table 1) (7). 
 
Male circumcision is modeled in one of two ways. A newborn circumcision program is simulated in 
which 35% of newborns are circumcised throughout the simulation (Web Table 1). To simulate adult 
voluntary medical male circumcision interventions, a defined proportion of adult males within a specified 
age range are circumcised to reach a target proportion. Circumcision is assumed to reduce the per-act HIV 
transmission probability by 56% (8-10, 42). 
 
Testing and Treatment Cascades. The HIV-CDM structure allows infected individuals to pass through the 
testing and treatment cascades provided by CEPAC-I (31, 43, 44) and the potential benefits of various 
testing and treatment assumptions on epidemic dynamics can be examined. In the testing cascade, 
individuals access care and are offered an HIV test based on clinical symptoms. A proportion of 
individuals accept HIV tests and a proportion are linked to care if the test is positive. When individuals 
link to care and subsequently meet the CD4 ART start threshold, they enter the treatment cascade in 
CEPAC-I (39). Individuals begin treatment according to treatment availability through ART expansion. 
Those receiving ART have a probability of HIV-RNA suppression (45); for those who reach suppression, 
a monthly probability of late ART failure is assigned (45). Additionally, individuals can be lost to follow-
up at a specified yearly rate (Web Table 1) (46, 47).  
 
A detailed description of historical ART rollout in South Africa for the period between 2002 and 2013 
can be found in Web Appendix 1. For the period after 2013, two types of continued ART expansion were 
considered: slow and rapid. In slow expansion, the amount of available treatment increased at a historical 
ratio with growing population size. In rapid expansion, all individuals who tested positive for HIV 
received treatment by 2017 (details in Web Table 2).  
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Elimination 
We defined elimination as achieving an annual HIV incidence of less than 1 new infection per 100,000 
person-years. The year at which elimination is reached can be directly estimated from the model 
incidence output. 
 
Historical ART rollout in the HIV-CDM 
In the period between 2002-2013 historical levels of ART following national treatment guidelines were 
assigned in the HIV-CDM to ensure accurate predictions. Because the model population size is smaller 
than the true South African population, the number of individuals receiving ART in the model was 
standardized yearly to historical data from South Africa between 2002 and 2013 and interpolated monthly 
(see Web Figure 1 and Web Table 2)  (48-50). Historical South African treatment guidelines (51-54) were 
used to assign individuals to treatment in CEPAC-I, assuming availability. These treatment guidelines are 
summarized in Web Table 3. The eligibility, testing, and treatment access process are outlined in Web 
Figure 1 and Web Table 3. In cases of limited treatment availability, treatment was assigned to a new 
individual when an individual on ART died or when treatment availability expanded.  
 
Scenarios 
We analyzed primary prevention, testing, and treatment interventions to determine which produce the 
largest decrease in HIV prevalence and incidence, and largest increase in infections averted. We 
constructed scenarios to evaluate HIV interventions, starting in 2013 through 2063, by varying multiple 
parameters (Table 1): the proportion of adult males circumcised; condom usage in each type of 
partnership; the interval at which individuals get tested for HIV; HIV test acceptance rates; linkage to care 
rates following a new HIV diagnosis; probability of ART suppression at 6 months; monthly probability of 
late ART failure; yearly LTFU on ART; and the CD4 threshold for initiation of ART. All other inputs 
were assumed to remain constant for each of these scenarios (Web Table 1). We assumed perfect HIV test 
sensitivity and specificity for those with chronic and late-stage HIV infection.  
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In Scenario 1 (Status Quo Continued), current inputs for testing, treatment, and primary prevention were 
specified along with a slow expansion of ART (1% increase in treatment slots per year). This scenario 
was used as the comparator for all analyses. In the perfect scenario (Scenario 2 – Perfect), testing and 
treatment expanded rapidly to reach universal coverage in 4 years. In Scenario 2, the testing cascade was 
assumed to be perfect (i.e. everyone was offered a test, accepted it, and was linked to care if positive) 
with complete HIV suppression (including no late failure) and no losses to follow-up. Additionally, all 
males were circumcised and condoms were used in all sex acts. We also evaluated improvements to the 
testing and treatment cascades in the absence of primary interventions (Scenario 3 – Perfect Testing and 
Treatment Only). In the remaining scenarios (Table 1), we varied primary prevention intervention 
parameters individually (Scenario 4 – Universal Circumcision, Scenario 5- Universal Condom Usage). 
Lastly, we examined a higher ART start CD4 threshold (Scenario 6), and estimated the changes in HIV 
prevalence, incidence and infection averted with a perfect testing cascade (Scenario 7) and perfect 
treatment components, including no LTFU and perfect HIV suppression (Scenario 8).    
 
Every scenario was evaluated across each of the 564 calibration-derived parameter sets that collectively 
represent 90% of the posterior probability weight-to-fit to national prevalence and incidence data from 
1990-2002 (35). Average results are shown for HIV prevalence, incidence, and infections averted 
calculated from normalized calibration weights (35).  
 
Robustness of Predictions 
The calibration approach used in our model (35) allows testing of the robustness of predictions while 
varying multiple parameters simultaneously. Parameter-dependence of the findings of the model was 
assessed by examining how consistently different scenarios are ranked on the value of the outcome 
measures (incidence, prevalence, and infections averted) using these different parameter sets. For each of 
the scenarios, annual HIV incidence in 2050 was ranked from highest to lowest across each of the 564 
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parameter sets. If the same parameter sets were ranked highest for each of the
 
scenarios, one can conclude 
that results were parameter-set independent and transmission dynamics depended primarily on the 
scenario of interest. Conversely, if there was wide variety in outcome rankings for each of the scenarios, 
one may expect that calibrated parameter values mattered in determining the scenario’s epidemiologic 
role  in HIV prevention or elimination. 
 
Role of the  Testing and Treatment Cascade and Acute Infection Period in Achieving HIV Elimination 
We varied assumptions on ideal testing and treatment programs, the use of HIV-RNA as ART start 
criterion, condom usage in different partnership types (Web Table 4), acute infection period, and 
elimination thresholds in sensitivity analyses.  
 
To understand the most influential portions of the testing and treatment cascade, we implemented the 
most ambitious value of each element independently with the status quo assigned for all other parameters 
(Web Table 4). In Scenarios 9-11, the test interval, test acceptance, and linkage to care are perfected 
independently, representing improvements to different elements of the testing cascade. In Scenarios 12 
and 13, we improved the suppression rates on treatment and LTFU rates to understand the sensitivity of 
interventions to changes in the treatment cascade. 
 
We examined a high HIV-RNA level for the treatment threshold (HIV-RNA > 30,000 copies/mL, 
Scenario 14) and additionally examined the use of a lower HIV-RNA level for the ART start criterion by 
treating individuals with HIV-RNA >10,000 copies/mL (Scenario 15). The HIV-RNA ART start criterion 
is implemented in the same way as the CD4 ART start criterion in CEPAC-I. 
 
We assessed the sensitivity of model predictions to the extent of condom usage using six different 
sensitivity scenarios (Web Table 4) since universal condom usage is practically unattainable (55). In 
Scenario 16, we evaluated CSW condom interventions by modeling all partners of CSW using condoms 
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during each partnership. In Scenario 17, we evaluated 100% condom use in one-off partnerships (casual 
and CSW). In Scenario 18, we estimated 100% condom use in casual partnerships. In Scenario 19, we 
assessed improving condom usage by 50% in all partnership types and by 90% in Scenario 20 compared 
to status quo values. In Scenario 21, we examined reducing  the effectiveness of condoms to 65% (from 
80%) in the universal condom usage scenario.   
 
RESULTS 
Historical ART Rollout: Validation 
When ART was rolled out at historical rates from 2002-2013, our model’s average HIV prevalence curve 
somewhat overestimated the UNAIDS model (50). Despite this, prevalence was comparable to historical 
antenatal clinic data (56) and Africa Centre Cohort prevalence data (57) in South Africa during the same 
time period (Web Figure 2).  
 
HIV Elimination 
Scenario 1 (status quo in 2013 for all interventions continued) resulted in a 33% increase in prevalence 
(Figure 1) and a slight increase in incidence (Figure 2) from 2013 to 2063. Only Scenario 2, in which all 
interventions are perfected, achieved elimination of HIV on a 50-year time scale (Web Figure 3). In this 
scenario, the year of elimination varied by parameter set from 2046 to 2064, with random variability as 
incidence rates approached zero. In this setting, elimination was not always permanent; in some 
simulations, the elimination threshold was reached but incidence increased above it again following small 
clusters of transmission among high-risk men and their low-risk partners (Web Figure 3, inset).  
 
In the absence of universal primary prevention interventions, the use of perfect testing and treatment 
(Scenario 3) produced immediate reductions in incidence followed by a slow continuous decline, although 
elimination was not reached (Figure 2). Of all new infections from 2043-2063, 60% were attributed to 
infectors in the acute infection period indicating that continued transmissions from acutely infected 
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individuals prevented further decreases in incidence. Universal condom use (Scenario 5), in the absence 
of perfect treatment and testing, resulted in a 99% reduction in incidence over 50 years, but only reached 
elimination for a few parameter sets. The remaining scenarios (6-8) did not produce a weighted average 
incidence below 1.5 cases per 100 person-years within 50 years (Figure 2) and showed substantial 
increases in prevalence over 50 years (Figure 1). Short-term reductions in incidence were seen in 
Scenarios 4 (Universal Circumcision), 6 (Ambitious CD4 Threshold), and 8 (Perfect Treatment 
Components) within 20 years of the intervention, but these reductions were not maintained; higher steady 
states were reached at 21%, 11%, and 26% reductions from 2013 incidence, respectively. Perfecting the 
testing cascade (Scenario 7) reduced incidence little more than the Status Quo due to similar increases in 
ART slots in both scenarios, which created a bottleneck in downstream treatment with increased testing. 
 
Infections Averted 
When compared to the continuation of the Status Quo (Scenario 1), Scenarios 2, 3, and 5 averted 99%, 
88%, and 93% of anticipated new infections from 2013 to 2063, respectively (Table 2).  
 
Robustness of Predictions 
The ranking of scenarios within parameter sets was most consistent for those scenarios that resulted in 
dramatic decreases in incidence (Scenarios 2, 3, and 5, Web Figure 4). Among scenarios with modest 
decreases in incidence (Scenarios 1, 4, 6-8), the order of scenarios was less clear, indicating that the 
change in outcomes due to these intervention scenarios was more parameter-dependent.   
 
Role  of the Testing and Treatment Cascade and Acute Infection Period in Acheiving HIV Elimination 
When each element of the testing and treatment cascade is improved to an ambitious value independently, 
we see minor reductions in HIV incidence and prevalence compared to the situation in which all 
improvements to the testing and treatment cascade are made at once (Scenario 3). Improvements to the 
treatment cascade decrease HIV incidence more than improvements to the testing cascade when 
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implemented independently (Web Figures 5 and 6, Web Table 5), in large part due to the limited 
availability of ART in these scenarios. Improving 6-month ART suppression rates and reducing LTFU 
resulted in sustained incidence reductions of 13% and 11%, respectively, over the course of the 50-year 
simulation, representing the largest reduction of incidence for independent testing and treatment 
components (Web Figures 5 and 6, Web Table 5).  
 
Using an HIV-RNA threshold to determine ART eligibility led to reductions in HIV incidence over time 
and dramatic increases in prevalence, but was not superior to the most ambitious CD4 ART start 
threshold results (Web Figures 7 and 8, Web Table 5). We captured the total potential prevention benefit 
of this strategy by treating everyone with HIV-RNA > 30,000 copies/mL. Additionally, we observed that 
modest increases in condom usage led to less dramatic reductions in HIV incidence (Web Figures 9 and 
10, Web Table 5).  
 
The magnitude of the epidemic at its peak was found to be proportional to the length of the acute period. 
Changing the acute infection length had little influence on Scenario 1 but did influence Scenario 2 by 
making prevention interventions weaker for shorter acute periods. The HIV-CDM was calibrated with a 
3-month acute infection period; changing the length of acute infection breaks the calibration and as such 
results are not shown.  
 
DISCUSSION 
We forecasted the potential for multiple HIV prevention interventions to change HIV incidence and 
prevalence in South Africa over a 50-year time horizon. If all interventions are perfected and combined, 
elimination is predicted within 50 years. If the testing and treatment cascades are perfected, elimination is 
within reach but not achieved due to transmissions occurring during acute infection. Continuing current 
rates of testing and treatment in South Africa does not achieve HIV elimination.  
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The timeline for HIV elimination after a dramatic scale-up in testing, treatment, and primary prevention 
interventions was longer than previously predicted (32). This is likely due to the level of detail presented 
in our model and the use of a more stringent cut-off for elimination than previous analyses (32). Even 
when considering a less stringent cut-off, such as a sustained 75% reduction in incidence, extreme and 
implausible conditions need to be met to reach elimination (Scenarios 2, 3, and 5). The variability in our 
predicted results, due to multiple calibrated parameter sets, adds robustness to our predictions and 
highlights the importance of rigorously calibrating complex models to multiple data sources.  
 
Despite dramatic reductions in HIV incidence in the most ambitious scenarios, we observed that a group 
of transmitters, primarily high-risk men transmitting to low-risk women, caused HIV to persist for 
extended periods of time, delaying elimination. Despite receiving numerous interventions and ART, these 
high-risk men were having enough sex acts to continue transmitting HIV to their low-risk partners (most 
high-risk partners had already been infected). The stratification of our model population into high- and 
low-risk, with a complex risk-, age-, and relationship-dependent sexual mixing structure, the inclusion of 
CSW, variations in condom usage, appropriate circumcision efficacy, changes in transmission potential as 
a result of detailed treatment modeling and a thorough calibration procedure distinguish this model from 
previously published analyses (32).   
 
Improvement in any single aspect of the testing and treatment cascade leads to small overall changes in 
prevalence and incidence, because failures at other steps limit overall effectiveness. Reducing LTFU or 
improving ART suppression decrease incidence because they affect viral load and infectiousness, but do 
not reduce incidence enough on their own to lead to significant changes in prevalence. In these situations, 
an individual’s transmission potential remains high, alongside lower community HIV-RNA and increased 
access to treatment. Primary prevention interventions, such as condom usage and circumcision, help 
reduce HIV incidence through a rapid reduction in transmission potential and subsequently influence 
prevalence on a long-term scale. Despite dramatic decreases in incidence through combined testing and 
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treatment interventions, we found that it is difficult to move the epidemic towards elimination without 
universal adoption of the primary prevention methods of circumcision and condom usage, which are more 
likely unattainable. Future analyses should evaluate the potential that pre-exposure prophylaxis may have 
as a primary prevention intervention.  
 
This analysis was constrained by assumptions implicit in the model structure. The HIV-CDM does not 
account for non-heterosexual HIV transmission, and therefore cannot account for prevention benefits or 
risks via non-heterosexual transmission routes. Furthermore, the model does not account for mother-to-
child transmission or infected adolescents entering the sexually active pool. We have not implemented 
behavioral changes after the start of aggressive testing and treatment interventions that are expected to 
occur in real-world populations (58). The implementation of multiple concurrent prevention interventions 
may lead to participant fatigue but neither this nor heterogeneity in testing behavior is examined in this 
analysis. Finally, we have assessed testing, treatment, and primary prevention at idealized levels. Whether 
moving each of these components of care from the status quo towards ideal is equally feasible is not clear. 
Despite these limitations, the HIV-CDM is one of the most detailed individual-based models in the HIV 
transmission and prevention literature (21) incorporating a great deal of flexibility in modeling both 
behavior and biology. Additionally, the use of agent-based simulations allowed examination of outcomes 
for a large range of scenarios, something unattainable in large and complex community randomized trials 
(24). In developing this model, we have expanded upon the capacity of the CEPAC-I Disease Model to 
simulate sexual behavior’s influence on HIV transmission. The extensive calibration of the HIV-CDM in 
the era prior to the introduction of ART helps to ensure that the behavior represented in the model 
produces accurate epidemic dynamics in the absence of ART.  
 
With the continuation of current levels of HIV prevention, testing and treatment in South Africa, we 
conclude that it will be difficult, and perhaps impossible, to decrease HIV prevalence in the population, 
partly due to increasing survival on ART. We have shown that even after implementation of an aggressive 
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and highly optimistic ART expansion, alongside changes in condom usage and circumcision patterns, the 
potential for HIV elimination would be lower than previously estimated (32). Treatment as prevention 
produces the greatest reduction in transmission potential in a population when used to “hit hard and fast”, 
as suggested by the recent UNAIDS fast-track guidelines and the Strategic Timing of Antiretroviral 
Treatment study results (34, 59). In the absence of an effective HIV vaccine, if HIV transmission 
potential is not reduced quickly and substantially, the number of people on ART is expected to remain 
high as individual survival outweighs the population-level reduction in transmission. Large upfront 
investments from governments and international partners would be needed to make this dramatic decrease 
in incidence possible (60). While increased attention has been given to testing and treatment interventions 
in Sub-Saharan Africa, primary prevention interventions could also reduce HIV incidence. Efforts 
towards increasing uptake of primary prevention strategies, such as circumcision and pre-exposure 
prophylaxis, alongside ongoing prevention efforts, may lead the way to faster and more effective 
reductions in HIV incidence in South Africa. 
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Figure 1. Human immunodeficiency virus (HIV) prevalence from 1990-2063 in all combination intervention scenarios simulated in South 
Africa starting in 2013. HIV prevalence is defined as the total number of living HIV cases among sexually active individuals divided by the total 
number of sexually active individuals alive at the defined time point. The bold black solid line represents Scenario 1 (Status Quo Continued), 
black dotted line represents Scenario 2 (Perfect), black dashed line represents Scenario 3 (Perfect Testing and Treatment Only), black line with 
triangles represents Scenario 4 (Status Quo, Universal Circumcision),  double black line represents Scenario 5 (Status Quo, Universal Condom 
Usage), black line with circles represents Scenario 6 (Status Quo, Ambitious CD4 Threshold), black line with crosses represents Scenario 7 (Status 
Quo, Perfect Testing Components), and black line with squares represents Scenario 8 (Status Quo, Perfect Treatment Components). All scenarios 
are defined in Table 1. Prevalence decreases quickly in Scenarios 2, 3, and 5 while prevalence increases in all other scenarios. A steady state is 
reached in Scenarios 6 and 8. 
Abbreviations in figure: HIV= human immunodeficiency virus. 
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Figure 2. Human immunodeficiency virus (HIV) incidence from 1990-2063 in all combination intervention scenarios simulated in South 
Africa starting in 2013. HIV incidence represents an annual HIV incidence among sexually active individuals. The bold black solid line 
represents Scenario 1 (Status Quo Continued), black dotted line represents Scenario 2 (Perfect), black dashed line represents Scenario 3 (Perfect 
Testing and Treatment Only), black line with triangles represents Scenario 4 (Status Quo, Universal Circumcision),  double black line represents 
Scenario 5 (Status Quo, Universal Condom Usage), black line with circles represents Scenario 6 (Status Quo, Ambitious CD4 Threshold), black 
line with crosses represents Scenario 7 (Status Quo, Perfect Testing Components), and black line with squares represents Scenario 8 (Status Quo, 
Perfect Treatment Components). All inputs for scenarios are defined in Table 1. HIV incidence decreases dramatically in Scenarios 2, 3, and 5 but 
only reaches elimination in Scenario 2. Initial HIV incidence decreases are seen in Scenarios 6 and 8 but level off at slightly lower levels from the 
2013 incidence. 
Abbreviations in figure: HIV= human immunodeficiency virus. 
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Table 1. Scenario Input Table. Scenarios used  to estimate the changes in HIV incidence, prevalence and infections averted varying primary, testing, and 
treatment interventions on HIV elimination in South Africa from 2013 to 2063. 
Scenario Description 
ART 
Expansion 
Type 
Male Circ 
Prop at 
Birth (%) 
Condom 
Usage (%) 
HIV 
Testing 
Interval 
HIV Test 
Accept Rate 
(%) 
Linkage to 
Care (%) 
ART Supp 
at 6 mo. 
(%) 
Monthly 
ART late 
fail prob 
(%) 
LTFU 
on ART 
(%) per 
year 
CD4 ART 
Start 
Threshold 
(2013) 
1 
Status Quo 
Continued 
Slow 35 12-50 1 year 50 46.80 78 0.1 9.90 <350/µl 
2 Perfect Rapid 100 100 1 month 100 100 100 0 0 All CD4 
3 
Perfect 
Testing and 
Treatment 
Only 
Rapid 35 12-50 1 month 100 100 100 0 0 All CD4 
4 
Status Quo, 
Universal 
Circumcisio
n 
Slow 100 12-50 1 year 50 46.80 78 0.1 9.90 <350/µl 
5 
Status Quo, 
Universal 
Condom 
Use 
Slow 35 100 1 year 50 46.80 78 0.1 9.90 <350/µl 
6 
Status Quo, 
Ambitious 
CD4 
Threshold 
Slow 35 12-50 1 year 50 46.80 78 0.1 9.90 All CD4 
7 
Status Quo, 
Perfect 
Testing 
Component
s 
Slow 35 12-50 1 month 100 100 78 0.1 9.90 <350/µl 
8 
Status Quo, 
Perfect 
Treatment 
Component
s 
Slow 35 12-50 1 year 50 46.80 100 0 0 <350/µl 
Abbreviations: accept = acceptance; ART= antiretroviral therapy; circ = circumcision; HIV= human immunodeficiency virus; LTFU = loss to follow-up; mo. = 
month; prob = probability; prop = proportion; supp = virologic suppression rate. 
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Table 2. Infections Averted Results. Tabulated total infections, infections averted, and percent averted for all scenarios of an examination for the 
potential for HIV elimination in South Africa from 2013 to 2063.  
Scenario Description Total Incident 
Infections (2013-2063) 
(No.) 
Total Infections Averted   
(vs. Scenario 1 – Status Quo 
Continued) (No.) 
Percentage of Infections 
Averted (vs. Scenario 1 – 
Status Quo Continued) 
(%) 
1 Status Quo Continued 278,373 -- -- 
2 Perfect 2,014 276,359 99 
3 Perfect Testing and 
Treatment Only 
33,858 244,515 88 
4 Status Quo, Universal 
Circumcision 
219,236 59,137 21 
5 Status Quo, Universal 
Condom Usage 
20,914 257,459 93 
6 Status Quo, Ambitious 
CD4 Threshold 
241,162 37,211 13 
7 Status Quo, Perfect 
Testing Components 
278,648 -275 -0.10
a 
8 Status Quo, Perfect 
Treatment Components 
220,823 57,550 21 
a
The increase in infections is due to the recruitment of healthier people for treatment with a more extensive testing campaign. This leaves 
fewer spots for those who may be more viremic, causing more infections in the long term. 
Abbreviations: HIV=human immunodeficiency virus. 
 
 
 
 
 
 Web Table 1. Base-case Inputs for a Model of HIV Elimination in South Africa from 2013-2063. 
Parameter (reference) Value 
Population size at model initiation 100,000 
Number of births per person per month (56) 0.0022 
Proportion of the population who is male
 
(MA, 56) 0.50  
Age of first sex (57-59) 17 years  
Proportion of newborn males circumcised (57, 58, 60, 
61) 
0.35  
Probability of a female becoming a CSW/Proportion 
CSW at baseline 
0.01-0.04** 
Proportion of males in the HR group 0.07-0.4 
Proportion of non-CSW females in the HR group 0.01-0.3** 
Sexual Partnership Characteristics   
Steady Partnerships  
Duration of partnership
b
 (62-64) 10.20 years (SD 7.80 years)  
Number of sex acts per partnership per month
c
 (65-67) 9 
Probability of male condom use per sexual act
d
 
(%)(59, 68, 69) 
12 (SD 6)  
Regular Partnership  
Duration of partnership
b
 (55, 56) 13.50 months (SD 9 months) 
Number of sex acts per partnership per month 4-11** 
Probability of male condom use per sexual act (%) 
(57, 59, 70, 71) 
29 (SD 15)  
Casual Partnership  
Duration of casual partnership (MA) 1 sexual act
 
 
Number of sex acts per partnership per month
c
 (MA) 1
 
 
Probability of male condom use per sexual act
d
(%) 
(57, 59, 70) 
37 (SD 19)  
CSW Encounters  
Duration of CSW encounter (MA) 1 sexual act  
Number of sex acts per partnership per month
c
 (MA) 1  
Probability of male condom use per sexual act
d
 (%) 
(68) 
50 (SD 25)  
 Parameter (reference) Value 
Partnership Selection Criteria  
Average number of years younger the female is 
compared to male partner (steady, regular and casual)
b
 
(49, 57, 58) 
5  (SD 2.50)  
Average number of years younger CSW is compared 
to male partner
b
 (72, 73)
 
13 (SD 6·50)  
Sexual Network Parameters  
High-risk multiplier 1-10** 
High-risk multiplier CSW  30-100** 
Partner acquisition multiplier while in steady 
partnership or low-risk males 
0-1** 
Assortativeness parameter for steady, regular, and 
casual partnerships 
0.2-0.8** 
Intervention Efficacy 
Circumcision Efficacy (%) (8-10, 40) 56  
Condom Efficacy (%) (7) 80  
HIV Testing  
Intervention HIV testing interval (MA) 1 year 
 
Average background HIV test frequency (52) Every 10 years  
Sensitivity of HIV test (%) (MA) 100  
Specificity of HIV test (%) (MA) 100  
Sensitivity in acute phase
a
 of HIV test (%) (MA) 0  
Linkage to care (%) (52) 46.8  
Mean initial CD4 cell count, cells/μl   
Acute, primary
a
 HIV infection (74) 884  
ART   
CD4 ART start criteria in 2013 (75) <350 cells/µl  
ART Suppression at 6 months (%) (43) 78  
Monthly late ART failure probability (%)(43) 0.1  
ART program loss to follow-up at 12 mo. (%) (44, 45) 9.9 
Natural History  
Mean monthly CD4 decline (cells/μl) by HIV RNA 
level (39, 76) 
 
 Parameter (reference) Value 
>30,001 copies/ml 6.4 
10,001-30,000 copies/ml 5.4 
3,001-10,000 copies/ml 4.6 
501-3,000 copies/ml 3.7 
<500 copies/ml 3.0 
Probability of transmission per sexual act by HIV 
RNA (copies/ml) (66, 67, 77, 78) 
 
0-500 0.0001 
501-3,000 0.0012 
3,001-10,000 0.0012 
10,001-30,000 0.0014 
30,001 + 0.0023 
Acute infection
a 
0.0082 
Late-stage infection
a 
(67) 0.0036  
Abbreviations: ART= antiretroviral therapy; CSW= commercial sex worker; HIV=human 
immunodeficiency virus; HR=high risk; MA
 = 
Model assumption; mo.=month;  
a
 Acute infection is the first three months post-infection; chronic infection immediately follows primary 
infection and continues until the individual’s CD4 count drops below 50/mm3; late-stage infection occurs 
when the individual’s CD4 drops below 50/mm3. 
b
 The duration of partnerships and the average number of years between partners are parameters chosen 
from a normal distribution with the denoted mean and standard deviation. 
c
 The number of sex acts per partnership per month parameter is chosen from a Poisson distribution with 
the denoted mean (and standard deviation). 
d
 The probability of a condom use in each partnership parameter is chosen from a beta distribution. This 
distribution is converted to a normal distribution with the denoted mean and standard deviation for 
presentation in table. 
** These parameters were varied in the calibration procedure. Each of the 564 parameter sets has a 
randomly selected value from within these ranges for each of the 12 varied parameters. 
 Web Appendix 1 
Cost-effectiveness of Preventing AIDS Complication International Model (CEPAC-I)  
The CEPAC-I Disease Model is a computer-based, state-transition, Monte Carlo simulation model of the 
progression and outcomes of HIV disease in a hypothetical cohort of patients (1-5). Each individual 
patient’s clinical course is followed from the time of entry into the model until death. A running tally is 
maintained of all clinical events, the length of time spent in each health state, and the cost and quality of 
life associated with each health state. Health states are chosen to be both descriptive of a patient’s current 
health (CD4 count, HIV RNA, relevant history, quality of life, and resource use) and predictive of disease 
progression (immune system deterioration, onset and relapse of OIs (Web Table 6), toxic reactions to 
medications, resistance to therapy, and mortality) (6-8). The model defines three general categories of 
health states: chronic, acute, and death. Most of the time, patients reside in one of the chronic states, 
where progression of disease and immune system deterioration (CD4 decline) take place. Patients who 
develop an acute complication (eg: an OI or drug-related toxicity) temporarily move to an acute health 
state, where quality of life is lower and both resource use and mortality rates are higher. Deaths can occur 
in either a chronic or an acute state and can be attributed to a particular OI, chronic AIDS, or non-AIDS 
related causes.  
 
The chronic and acute health states are stratified by: current and nadir CD4 cell count (>500 cells/μL; 
301–500 cells/μL; 201–300 cells/μL; 101–200 cells/μL; 51–100 cells/μL; and 0-50 cells/μL) and current 
and set-point HIV RNA level (>30,000 copies/mL; 10,001–30,000 copies/ mL; 3,001–10,000 copies/ mL; 
501–3,000 copies/ mL; 51-500 copies/ mL; 0-50 copies/mL). Upon entry into the model, a patient is 
randomly assigned to a health state based upon a set of user-specified probability distributions.  
 
At the start of each one-month cycle, the model records the patient’s CD4 cell count, HIV RNA, history 
of acute illness, and current therapies and uses these characteristics to determine the probabilities that 
indicate movement to a new state in the subsequent month. Monthly probabilities of events are derived 
from public use datasets and translated into risk functions for the model (9). These risk functions embody 
the key parameters of the natural history of HIV illness, AIDS, and OIs, including: rates of disease 
progression, OI risks (Table S5), survival probabilities, and the effects of therapy. The model treats HIV 
RNA as the primary driver of immune system deterioration, and thus the assigned HIV RNA determines 
the rate at which the patient’s CD4 cell count will decline in the absence of therapy. Patients with a 
history of OIs have a higher risk of recurrence, depending on CD4 cell count and current use of ART (7).  
 
 The efficacy of ART is estimated from data on viral suppression and CD4 cell count change over time, as 
reported in randomized trials (10-12).  
 
Web Table 2. Rollout Specifications. This table indicates the population size and historical treatment 
rollout numbers in South Africa from 2002-2013. Because the model population size is smaller than that 
of the actual South African population, a ratio is calculated from these numbers which is used to scale the 
model population size to determine the amount of treatment available in the model run. After 2013, 
assumptions are made about the speed of ART rollout (rapid or slow) by changing the ratio. 
Year Population 
Size (in 
millions)(15) 
Historical 
Number 
Infected (in 
millions)(16) 
Historical 
Number 
Being 
Treated(16, 
17) 
Historical 
Input Ratio 
Rapid 
Input Ratio 
Slow Input 
Ratio 
2002 40.00 4.68 15000 0.00040   
2003 41.00 4.95 26000 0.0010   
2004 41.80 5.15 55000 0.0010   
2005 42.50 5.32 206718 0.0050   
2006 43.40 5.46 324754 0.0070   
2007 44.60 5.59 458951 0.010   
2008 45.90 5.72 730183 0.016   
2009 47.40 5.82 971556 0.020   
2010 48.80 5.88 1389865 0.028   
2011 50.10 5.97 1702060 0.034   
2012 52.60 6.07 2150881 0.041   
2013     0.082 0.050 
2014     0.16 0.060 
2015     0.33 0.070 
2016     0.65 0.080 
2017     0.99 0.090 
2018     0.99 0.10 
2019     0.99 0.11 
2020     0.99 0.12 
2021     0.99 0.13 
2022     0.99 0.14 
2023     0.99 0.15 
2024     0.99 0.16 
2025     0.99 0.17 
..     .. .. 
2065     0.99 0.57 
 (A)  
 (B)  
 (C)   
Web Figure 1. Testing and treatment cascade in the CDM and CEPAC-I. (A) Prior to 2013, all individuals who are eligible for treatment are 
put on treatment if there is treatment available. This ensures that all historically available treatment is being used. (B) In the case where there is not 
enough treatment for all eligible individuals, the available treatment is randomly assigned among those eligible. Treatment becomes available 
when someone who is receiving treatment dies. (C) After 2013, the testing and treatment cascade probabilities begin to take effect. Individuals 
who are eligible for treatment are tested and can accept or reject the test. Of those who accept the test, some are linked to care. Once an individual 
is linked to care, they are given treatment, assuming the availability of treatment. 
 Web Table 3. Historical ART Treatment Guidelines. Assumptions for access to ART are highlighted in the table for each of the years in which 
a major treatment guideline was revised. We assumed that the first two years of ART distribution were dominated by individuals with severe OIs. 
We then followed the treatment guidelines published by the South African Department of Health for the subsequent years until present day.  
Year Treatment Guidelines  
 WHO Stage/OI CD4 
2002  4 Irrespective 
 3 Irrespective, including recurrent or 
persistent oral thrush and recurrent 
invasive bacterial infections 
2004 (18) 4, 3 Irrespective 
 1,2,3 <200/mm
3
 
2010 (19) TB <350/mm
3
 
 4 Irrespective 
 Irrespective <200/mm
3
 
2013 (20) 3,4 Irrespective 
 Irrespective <350/mm
3 
 
 
 Web Table 4. Sensitivity Analyses. The parameter values for the scenarios of interest for sensitivity analyses are outlined below. 
Scenario 
ART 
Expansion 
Type 
Male 
Circ 
Prop at 
Birth 
(%) 
Condom 
Usage 
(%) 
HIV 
Testing 
Interval 
HIV 
Test 
Accept 
Rate (%) 
Linkage 
to Care 
(%) 
ART 
Supp 
at 6 
mo. 
(%) 
Monthly 
ART late 
fail prob 
(%) 
LTFU 
on 
ART 
(%) 
CD4 
Threshold 
(2013) 
HIV RNA 
Threshold 
(2013) 
Scenario 9 – 
Status Quo, 
Perfect test 
interval 
Slow 35 12-50 1 month 50 46.8 78 0.1 9.9 <350 N/A 
Scenario 10 – 
Status Quo, 
Perfect test 
accept 
Slow 35 12-50 1 year 100 46.8 78 0.1 9.9 <350 N/A 
Scenario 11 – 
Status Quo, 
Perfect 
linkage to 
care 
Slow 35 12-50 1 year 50 100 78 0.1 9.9 <350 N/A 
Scenario 12 – 
Status Quo, 
Perfect 
suppression 
Slow 35 12-50 1 year 50 46.8 100 0 9.9 <350 N/A 
 Scenario 
ART 
Expansion 
Type 
Male 
Circ 
Prop at 
Birth 
(%) 
Condom 
Usage 
(%) 
HIV 
Testing 
Interval 
HIV 
Test 
Accept 
Rate (%) 
Linkage 
to Care 
(%) 
ART 
Supp 
at 6 
mo. 
(%) 
Monthly 
ART late 
fail prob 
(%) 
LTFU 
on 
ART 
(%) 
CD4 
Threshold 
(2013) 
HIV RNA 
Threshold 
(2013) 
Scenario 13 – 
Status Quo, 
Perfect 
LTFU 
Slow 35 12-50 1 year 50 46.8 78 0.1 0 <350 N/A 
Scenario 14 – 
Status Quo, 
Ambitious 
use of HIV 
RNA 
threshold for 
treatment 
Slow 35 12-50 1 year 50 46.8 78 0.1 9.9 N/A >30,000 
Scenario 15 – 
Status Quo, 
Ambitious 
use of lower 
HIV RNA 
threshold for 
treatment 
Slow 35 12-50 1 year 50 46.8 78 0.1 9.9 N/A <10,000 
 Scenario 
ART 
Expansion 
Type 
Male 
Circ 
Prop at 
Birth 
(%) 
Condom 
Usage 
(%) 
HIV 
Testing 
Interval 
HIV 
Test 
Accept 
Rate (%) 
Linkage 
to Care 
(%) 
ART 
Supp 
at 6 
mo. 
(%) 
Monthly 
ART late 
fail prob 
(%) 
LTFU 
on 
ART 
(%) 
CD4 
Threshold 
(2013) 
HIV RNA 
Threshold 
(2013) 
Scenario 16 – 
Status Quo, 
100% 
Condom 
Usage for 
CSW Only 
Slow 35 
Steady: 
12 
Regular: 
29 
Casual: 
37 
CSW: 
100 
1 year 50 46.8 78 0.1 9.9 <350 N/A 
Scenario 17 – 
Status Quo, 
100% 
Condom 
Usage for 
CSW and 
Casual 
Partnerships 
Slow 35 
Steady: 
12 
Regular: 
29 
Casual: 
100 
CSW: 
100 
1 year 50 46.8 78 0.1 9.9 <350 N/A 
Scenario 18 – 
Status Quo, 
100% 
Slow 35 
Steady: 
12 
Regular: 
1 year 50 46.8 78 0.1 9.9 <350 N/A 
 Scenario 
ART 
Expansion 
Type 
Male 
Circ 
Prop at 
Birth 
(%) 
Condom 
Usage 
(%) 
HIV 
Testing 
Interval 
HIV 
Test 
Accept 
Rate (%) 
Linkage 
to Care 
(%) 
ART 
Supp 
at 6 
mo. 
(%) 
Monthly 
ART late 
fail prob 
(%) 
LTFU 
on 
ART 
(%) 
CD4 
Threshold 
(2013) 
HIV RNA 
Threshold 
(2013) 
Condom 
Usage for 
Casual 
Partnerships 
Only 
29 
Casual: 
100 
CSW: 50 
Scenario 19 – 
Status Quo, 
20% 
Increase in 
Condom 
Usage for all 
Partnership 
Types 
Slow 35 
Steady: 
14 
Regular: 
35 
Casual: 
44 
CSW: 60 
1 year 50 46.8 78 0.1 9.9 <350 
N/A 
 
Abbreviations in table: circ = circumcision, prop = proportion, accept = acceptance, supp = suppression rate, mo. = month, LTFU = loss to 
follow up, prob = probability 
 
 
 Web Figure 2. Historical ART Rollout (1990-2013). The predicted HIV prevalence from each of the 
HIV-CDM’s 90% weight to fit is depicted above with gray lines, in comparison to South African 
antenatal clinic data (16) and the Africa Centre Cohort prevalence data (22). The UNAIDS model 
predictions are much lower after the introduction of ART due to a lack of observed survival benefit of 
ART.  
 
 
  
 
Web Figure 3. Time to Elimination for Perfect Scenario 2. The grey lines in this figure represent each of the 564 
parameter sets that contribute the top 90% of the weight to fit from the calibration procedure; the black line represents 
their weighted average. The horizontal red line represents the elimination threshold of 1 case per 100,000 person-years. 
The blue line represents an elimination threshold of 1 case per 10,000 person-years. The time to elimination would occur 
between 2047 and 2063 with an aggressive testing and treatment campaign and perfect primary interventions. 
  
Web Figure 4. Robustness of Incidence Predictions. Boxplots of the relative ranking of scenarios 
within particular parameter sets. More variation between parameter sets occurs among scenarios with 
lower reductions in incidence compared to those with higher reductions in incidence. 
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Web Figure 5.  HIV Prevalence Curves for Independently Perfect Testing and Treatment Interventions. Independent changes to the testing 
and treatment cascades do not have a long term impact on the trend for increasing prevalence in South Africa over a 50 year time horizon, with the 
exception of changes to HIV RNA thresholds, which result in a decrease in HIV prevalence compared with the status quo. 
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Web Figure 6. HIV Incidence Curves for Independently Perfect Testing and Treatment Interventions. Incidence is reduced slightly for 
independent changes to the treatment cascade, but no observable differences in incidence are realized with idealized treatment cascade elements. 
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Scenario 1 - Status Quo Continued
Scenario 7 - Status Quo, Perfect
Testing Components
Scenario 8 - Status Quo, Perfect
Treatment Components
Scenario 9 - Status Quo, Perfect Test
Interval
Scenario 10 - Status Quo, Perfect
Test Accept
Scenario 11 - Status Quo, Perfect
Linkage to Care
Scenario 12 - Status Quo, Perfect
Suppression
Scenario 13 - Status Quo, Perfect
LTFU
 Web Table 5. Infections Averted for Scenarios 9-19 for Sensitivity Analysis Runs. 
Scenario 
Total Incident 
Infections 
(2013-2063) 
Infections Averted 
(vs. Scenario 1 - Real) 
Percentage of 
Infections Averted 
(vs. Scenario 1 – 
Real) 
Scenario 1 – Status Quo 
Continued 
278373 -- -- 
Scenario 9 – Status Quo, 
Perfect Test Interval 
278636 -263 N/A 
Scenario 10 – Status Quo, 
Perfect Test Accept 
278514 -140 N/A 
Scenario 11 – Status Quo, 
Perfect Linkage to Care 
558748 -280375 N/A 
Scenario 12 – Status Quo, 
Perfect Suppression 
262563 15810 6% 
Scenario 13 – Status Quo, 
Perfect LTFU 
256765 21608 8% 
Scenario 14 – Status Quo, 
Ambitious HVL Threshold 
252085 26288 9% 
Scenario 15 – Status Quo, HVL 
Start Threshold > 10K 
247733 30640 11% 
Scenario 16 – Status Quo, 
100% Condom Use for CSW 
257600 20773 8% 
Scenario 17 – Status Quo, 
100% Condom Use for CSW 
and Casual Partnerships 
248450 29923 12% 
Scenario 18 – Status Quo, 
100% Condom Use for Casual 
Partnerships 
276643 1730 1% 
Scenario 19 – Status Quo, 20% 
Increase in Condom Use 
Across Partnerships 
261952 16421 6% 
  
Web Figure 7.  HIV prevalence curves for alternate ART starting policies. Test and treat and the alternate test and treat approach (based on a 
HIV viral load threshold) reduce prevalence over the next 50 years, but a larger reduction is observed with an ambitious CD4 threshold.  
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Web Figure 8.  HIV incidence curves for alternate ART starting policies. Test and treat and the alternate test and treat approach (based on a 
HIV viral load threshold) reduce incidence over the next 50 years, but a faster and larger reduction is observed with an ambitious strategy of 
treating everyone regardless of CD4 count (Scenario 6).  
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CD4 Threshold
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HVL Threshold
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 Web Figure 9.  HIV prevalence curves for alternate condom efficacy interventions. A campaign that 
focuses on improving condom usage among particular subgroups of the population or among a portion of 
the population is not as effective at reducing prevalence as a perfect intervention. With modest increases 
in condom usage across all partnership types (30-60% increase in condom use from Status Quo) we see 
that prevalence continues to increase over the 50 year period. Only after achieving greater than a 70% 
increase in condom usage does prevalence decline in the same period. Notably, these reductions are not as 
large in magnitude as the scenarios in which all partnerships are protected by condom use. The reductions 
in prevalence are proportional to the efficacy of condom use in all of our sensitivity analyses. Condoms 
have a larger impact in CSW partnerships than casual partnerships because CSW partnerships are more 
likely to involve high-risk individuals than casual partnerships. High risk individuals are more likely to be 
infected in our model structure. Focusing on condom interventions alone does not have a great impact on 
the epidemic trajectory. 
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 Web Figure 10.  HIV incidence curves for alternate condom efficacy interventions. Incidence is only 
reduced dramatically and quickly in the perfect condom intervention case. In all other variations, condom 
usage does not impact incidence dramatically. With modest increases in condom usage across all 
partnership types (30-60% increase in condom use from Status Quo) we see that incidence continues to 
remain stable over the 50 year period. Only after achieving greater than a 70% increase in condom usage 
does incidence decline in the same period. Notably, these reductions are not as large in magnitude as the 
scenarios in which all partnerships are protected by condom use. The reductions in incidence are 
proportional to the efficacy of condom use in all of our sensitivity analyses. Condoms have a larger 
impact in CSW partnerships than casual partnerships because CSW partnerships are more likely to 
involve high-risk individuals than casual partnerships. High risk individuals are more likely to be infected 
in our model structure.  
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 Web Table 6. Additional Natural History Input Parameters Used in CEPAC-I. 
 
 
Parameter Value 
Natural History  
Percent monthly risk of severe opportunistic infections 
(%)(21) 
 
Bacterial 0.08-0.71 
Fungal 0.02-2.22 
Tuberculosis 0.21-1.96 
Toxoplasmosis 0-0.060 
Non-tuberculosis mycobacteriosis 0-0.30 
Pneumocystis jiroveci pneumonia 0-0.12 
Other WHO stage 4-defining diseases 0.25-2.57 
 
Percent monthly risk of mild opportunistic disease (%) 
 
Fungal 0.59-3.51 
Other 2.51-3.10 
